Home/Filings/4/0001209191-23-033780
4//SEC Filing

Simson Jake 4

Accession 0001209191-23-033780

CIK 0001863127other

Filed

Jun 1, 8:00 PM ET

Accepted

Jun 2, 4:31 PM ET

Size

6.4 KB

Accession

0001209191-23-033780

Insider Transaction Report

Form 4
Period: 2023-05-31
Simson Jake
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-05-31+14,50014,500 total
    Exercise: $14.47Exp: 2033-05-30Common Stock (14,500 underlying)
Footnotes (2)
  • [F1]The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
  • [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Issuer

Tyra Biosciences, Inc.

CIK 0001863127

Entity typeother

Related Parties

1
  • filerCIK 0001863094

Filing Metadata

Form type
4
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:31 PM ET
Size
6.4 KB